Robert L. Coleman mainly focuses on Ovarian cancer, Internal medicine, Oncology, Cancer and Cancer research. His studies deal with areas such as Chemotherapy, Docetaxel, Targeted therapy, Disease and Biomarker as well as Ovarian cancer. Robert L. Coleman combines subjects such as Gastroenterology, Gynecology and Surgery with his study of Internal medicine.
His Oncology research is multidisciplinary, relying on both Veliparib, Clinical trial, Fallopian tube and Carcinoma. Robert L. Coleman interconnects Clinical endpoint and Drug development in the investigation of issues within Cancer. Robert L. Coleman has included themes like Germline mutation, Endocrinology, PARP inhibitor, Ovarian carcinoma and Combination therapy in his Cancer research study.
His primary scientific interests are in Internal medicine, Oncology, Ovarian cancer, Cancer and Cancer research. His work in Internal medicine is not limited to one particular discipline; it also encompasses Rucaparib. His study on Gynecologic oncology is often connected to In patient as part of broader study in Oncology.
The concepts of his Ovarian cancer study are interwoven with issues in Angiogenesis, Disease, In vivo and Olaparib. His work deals with themes such as Cell growth, Cancer cell, Docetaxel, PI3K/AKT/mTOR pathway and Pharmacology, which intersect with Cancer research. His Chemotherapy study combines topics in areas such as Gastroenterology and Serous fluid.
His scientific interests lie mostly in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Cancer. Robert L. Coleman has researched Internal medicine in several fields, including Gastroenterology, Placebo and Rucaparib. His research in Oncology intersects with topics in Recurrent Ovarian Cancer, Maintenance therapy, PARP inhibitor and Olaparib.
His Ovarian cancer research includes themes of Stage, Targeted therapy, Clinical trial and Immunotherapy. The various areas that Robert L. Coleman examines in his Chemotherapy study include Multivariate analysis, BRCA mutation, Serous fluid and Cohort. His work carried out in the field of Cancer brings together such families of science as Cancer research and Intensive care medicine.
His scientific interests lie mostly in Internal medicine, Ovarian cancer, Oncology, Endometrial cancer and Clinical endpoint. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Placebo. His Ovarian cancer research is classified as research in Cancer.
His study in the fields of Primary peritoneal carcinoma under the domain of Cancer overlaps with other disciplines such as Median body. His Oncology study combines topics from a wide range of disciplines, such as Metastatic cervical cancer, Previously treated, Olaparib, PARP inhibitor and Maintenance therapy. His research integrates issues of Hysterectomy, Urology, Endometrial hyperplasia, EZH2 and Gene silencing in his study of Endometrial cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Premal H Thaker;Liz Y Han;Aparna A Kamat;Jesusa M Arevalo.
Nature Medicine (2006)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian.
The Lancet (2017)
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Pedro Tomas Ramirez;Michael Frumovitz;Rene Pareja;Aldo Lopez.
The New England Journal of Medicine (2018)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott.
Lancet Oncology (2017)
RNA interference in the clinic: challenges and future directions
Chad V. Pecot;George A. Calin;Robert L. Coleman;Gabriel Lopez-Berestein.
Nature Reviews Cancer (2011)
Latest research and treatment of advanced-stage epithelial ovarian cancer
Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog.
Nature Reviews Clinical Oncology (2013)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher.
The New England Journal of Medicine (2019)
Preclinical and clinical development of siRNA-based therapeutics
Gulnihal Ozcan;Bulent Ozpolat;Robert L. Coleman;Anil K. Sood.
Advanced Drug Delivery Reviews (2015)
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman;Mark F. Brady;Thomas J. Herzog;Paul Sabbatini.
Lancet Oncology (2017)
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer
Charles N. Landen;Blake Goodman;Ashwini A. Katre;Adam D. Steg;Adam D. Steg.
Molecular Cancer Therapeutics (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: